Glulisine

Three rapid-acting insulins have been approved in the United States lispro, aspart, and glulisine. Substitution of one or two amino acids in regular insulin results in the unique pharmacokinetic properties characteristic of these agents. Onset of action of rapid-acting insulins varies from 15 to 30 minutes, with peak effects occurring 1 to 2 hours following administration. 

Glulisine) acting insulin analogue produced in E. coli is replaced by a lysine and B29 lysine is replaced by glutamic acid. pharmaceuticals (USA)... 

Apidra (insulin glulisine) Yes 3-mL pen cartridge or OptiClik pen system... 

Injection 100 units/mL (insulin glulisine [rDNA]) Rx) Apidra (Aventis)... 

INSULIN GLULISINE Give within 15 minutes before a meal or within 20 minutes after starting a meal. Insulin glulisine is intended for subcutaneous administration and for use by external infusion pump. 

Insulin aspart, insulin glulisine - Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient. 

Lactation Lactating women may require adjustments in insulin dose and diet. It is unknown whether insulin glargine, insulin aspart, or insulin glulisine are excreted in significant amounts in breast milk. 

Insulin lispro, insulin aspart, insulin detemir, insulin glargine and insuline glulisine are human in-sullin analogues with the same mechanism of action. It should be noted however that the potency of insulin detemir was decreased four fold compared to human insulin. By changing amino acids on some locations absorption rates and the duration of action may be changed compared to human insulin. 

Disposable insulin pens are also available for selected formulations. These are regular insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin detemir, and several mixtures of NPH with regular, lispro, or aspart insulin (Table 41-4). They have been well accepted by patients because they eliminate the need to carry syringes and bottles of insulin to the workplace and while traveling. 

Insulin glulisine Insulin Separate CV and respiratory No, but the 12-month Standard Recombinant FDA-2004... 

Insulin Glulisine. Summary Basis for Approval, Pharmacology Review, 2004. http // www.fda.gov/cder/foi/nda/2004/21-629 Apidra.htm... 

---